Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Point’s big Splash falls short
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
SABCS 2023 – SERDs square off in combinations
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
Roche seeks alpha to defeat Novartis
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
A curate’s egg for MorphoSys
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
